Edition:
United Kingdom

Pernix Therapeutics Holdings Inc (PTX.OQ)

PTX.OQ on NASDAQ Stock Exchange Global Market

2.35USD
4:00pm GMT
Change (% chg)

$-0.03 (-1.26%)
Prev Close
$2.38
Open
$2.35
Day's High
$2.48
Day's Low
$2.30
Volume
7,792
Avg. Vol
24,474
52-wk High
$7.15
52-wk Low
$1.85

Chart for

About

Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as... (more)

Overall

Beta: 1.69
Market Cap(Mil.): $34.83
Shares Outstanding(Mil.): 11.53
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Pernix Therapeutics files for mixed shelf offering of up to $150 mln

* Pernix Therapeutics Holdings files for mixed shelf offering of up to $150 million - SEC filing‍​ Source text: (http://bit.ly/2jg0Ica) Further company coverage:

22 Nov 2017

BRIEF-Pernix Therapeutics posts Q3 revenue of $40.5 mln

* Pernix Therapeutics reports third quarter 2017 financial results

07 Nov 2017

BRIEF-Pernix Therapeutics announces sale of non-core product

* Pernix Therapeutics Holdings Inc - ‍sale of a non-core product Cedax to SI Pharmaceuticals LLC, for $2 million in gross cash proceeds​ Source text for Eikon: Further company coverage:

06 Nov 2017

BRIEF-Pernix Therapeutics says CFO and president Graham Miao resigns

* Pernix Therapeutics announces planned departure of chief financial officer

17 Oct 2017

BRIEF-Pernix Therapeutics reports qtrly net loss per common share $2.16

* Pernix Therapeutics reports second quarter 2017 financial results and provides business update

27 Jul 2017

BRIEF-Pernix Therapeutics files for resale of up to 10.1 million shares of common stock by selling stockholders - SEC filing‍​

* Pernix Therapeutics files for resale of up to 10.1 million shares of common stock by selling stockholders - SEC filing‍​ Source text: (http://bit.ly/2upc3NQ) Further company coverage:

24 Jul 2017

BRIEF-Pernix Therapeutics Holdings expects Q2 revenues to be between $33 mln and $35 mln

* Pernix Therapeutics pre-announces certain preliminary second quarter 2017 financial results

20 Jul 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $142.11 -0.35
Novartis AG (NOVN.S) CHF84.10 +0.30
Pfizer Inc. (PFE.N) $37.32 +0.12
Roche Holding Ltd. (ROG.S) CHF246.00 +1.90
Roche Holding Ltd. (RO.S) CHF246.80 +3.40
Merck & Co., Inc. (MRK.N) $56.50 +0.26

Earnings vs. Estimates